Casdin Capital’s C4 Therapeutics CCCC Stock Holding History

Casdin Capital’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-40,000	Closed	-$1.32M	–	52
2020 Q4	$1.32M	Buy	+40,000	New	+$1.16M	0.04%	52

Other funds holding CCCC

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Casdin Capital's CCCC Position: Q1 2021 in Review

Casdin Capital sold out of C4 Therapeutics (CCCC) in Q1 2021, closing a stake of 40,000 shares — an estimated $1.32M sold.

Casdin Capital first reported a position in CCCC in Q4 2020 and held it in 1 quarter. The position peaked at $1.32M in Q4 2020. 83 funds tracked by Wall St. Rank hold CCCC as of Q1 2021.

Casdin Capital reported no remaining C4 Therapeutics position as of Q1 2021 after selling out during the quarter.
Casdin Capital sold 40,000 C4 Therapeutics shares in Q1 2021, an estimated $1.32M.
Casdin Capital first reported a position in C4 Therapeutics in Q4 2020 and held it in 1 quarter.
Casdin Capital's C4 Therapeutics position peaked at $1.32M in Q4 2020.
83 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2021.

Based on Casdin Capital's 13F filing for Q1 2021, filed 17 May 2021.